Companies

SRPT · Biotech

Sarepta Therapeutics, Inc.

SEC company filings

Reported cash

USD 472,760,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

No upcoming event verified in tracked sources.

Drug pipeline

34 programs · 38 verified studies

Antibiotics

Phase

Phase4

Study status

Recruiting
View details

Sarepta Therapeutics, Inc.

IndicationDuchenne Muscular Dystrophy

Estimated study completion2027-08-31

AVI-4020 Injection

Phase

Phase1

Study status

Terminated
View details

Sarepta Therapeutics, Inc.

IndicationWest Nile Fever

Actual study completion2004-11

AVI-4020 Injection

Phase

Phase1

Study status

Completed
View details

Sarepta Therapeutics, Inc.

IndicationWest Nile Virus

Actual study completion2009-06

AVI-4065 Injection

Phase

Phase1 / Phase2

Study status

Terminated
View details

Sarepta Therapeutics, Inc.

IndicationHepatitis C

Actual study completion2007-01

AVI-4065 Injection

Phase

Phase1

Study status

Completed
View details

Sarepta Therapeutics, Inc.

IndicationEncephalitis

Actual study completion2009-06

AVI-4126 Injection (RESTEN-NG®)

Phase

Phase1

Study status

Completed
View details

Sarepta Therapeutics, Inc.

IndicationNeoplasms

Actual study completion2009-06

AVI-4658 (Eteplirsen)

Phase

Phase2

Study status

Completed
View details

Sarepta Therapeutics, Inc.

IndicationDuchenne Muscular Dystrophy

Actual study completion2012-06

AVI-4658 (Eteplirsen)

Phase

Phase2

Study status

Completed
View details

Sarepta Therapeutics, Inc.

IndicationDuchenne Muscular Dystrophy (DMD)

Actual study completion2017-08-16

AVI-4658 for Injection

Phase

Phase1 / Phase2

Study status

Completed
View details

Sarepta Therapeutics, Inc.

IndicationDuchenne Muscular Dystrophy

Actual study completion2010-12

AVI-5126

Phase

Phase2

Study status

Terminated
View details

Sarepta Therapeutics, Inc.

IndicationCardiovascular Disease; Coronary Artery Bypass

Actual study completion2009-03

1 / 5

7 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.